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Abstract 
The C3–C9 segment, (−)-16, of the polyene macrolide antibiotic protomycinolide IV (1a) was prepared in 
optically pure form from commercially available methyl (S)-2-methyl-3-hydroxypropionate in 12 steps giving 
17% yield. 
1. Introduction 
Protomycinolide IV and mycinolide IV (1a and 1b) are 16-membered polyene macrolides isolated from the 
culture broth of Micromonospora griseorubida sp. nov.[1]a The configuration of 1b was determined by X-ray 
diffraction analysis[1]b Conversion of 1b into 1a (tosylation of the 1° alcohol followed by reduction) 
demonstrated their structural association. While protomycinolide does not possess notable antibacterial 
activity, it has been shown to be a biosynthetic intermediate for the mycinamycin family of antibiotics which 
display significant activity against Gram-positive bacteria.[1]c Structural correlation between protomycinolide IV 
and other 16-membered macrolides (e.g. chalcomycin,[2]arosaramicin[2]b and tylosin[2]c) has recently led to a 
proposed biosynthetic pathway for their formation.[2]a In support of this mechanism, methyl mycinoate II (2a) 
and dicarboxymycinonic acid III (2b) have been isolated from the culture broth of a mutant of Micromonospora 
griseorubida which is unable to produce 1a.[1]d The total syntheses of 1a,[3] 2a and b[4] have been reported. 
We recently described a synthetic strategy for the preparation of dienolide 1 which relies on the ability of an 
Fe(CO)3 moiety to control C–C bond formation adjacent and remote to a coordinated diene (Scheme. 1).[5] To 
this end, we have reported the preparation of the C10–C17 segment 3 from (methyl 3,5-hexadienoate)Fe(CO)3 in 
a highly diastereoselective fashion, as well as model studies for generation of the C9–C10 dienone bond via 
Friedel–Crafts acylation. The synthesis of 1a by this methodology requires the functionalized acyl halide 4. We 
herein report the preparation of the C3–C9 segment in an enantioselective fashion. 
 
Scheme. 1. 
1.1. Enantioselective preparation of the C3–C9 segment 
The preparation of 17, in optically pure form, initially required preparation of the C4–C6 segment. There are 
many possibilities for generation of this stereotriad[6] and a double diastereoselective aldol condensation was 
chosen as our point of inception. Aldehyde (+)-7 was prepared from commercially available methyl (S)-2-methyl-
3-hydroxypropionate by protection, reduction[7] and oxidation[7] (70% yield, 3 steps, Scheme. 2). Aldol 
condensation of (+)-7 with N-propionyl-4(R)-methyl-5(S)-phenyloxazolidin-2-one[8] was effected by the use of 
dibutylboron triflate/NEt2iPr. The proton NMR spectrum of the crude product revealed one major diastereomer 
and a trace amount of at least one other diastereomer; however, the quantity of this very minor diastereomer 
was insufficient to determine its relative configuration or to determine a diastereomeric ratio. Chromatographic 
purification gave pure (+)-8 as a crystalline product (89%). The `anti-Felkin–syn-aldol' stereochemistry, which 
was expected on the basis of literature precedents,[9] was confirmed by X-ray diffraction analysis (Fig. 1).[10] 
 Scheme. 2. Reagents: (a) TBDPSCl/imidazole (93%); (b) DIBAL/THF (83%); (c) DMSO/(COCl)2/NEt3 (88%); (d) (N)-
propyl-4(R)-methyl-5(S)-phenyloxazolidinone/nBu2BOTf (89%); (e) NaOMe/MeOH (78%) 
 
Fig. 1. ORTEP view of (+)-8 
Treatment of (+)-8 with NaOMe/MeOH gave the methyl ester (+)-9 (78%) along with the recovered chiral 
auxilary (75%, Scheme. 2). Protection of the secondary alcohol with methoxymethyl chloride gave the ether (+)-
10 (95%, Scheme. 3). Reduction of ester (+)-10 with DIBAL (THF/toluene) gave the alcohol (+)-11 (92%), which 
was protected as its benzyloxymethyl ether (+)-12 (69%). Removal of the silyl protecting group with TBAF (83%) 
followed by Swern oxidation (84%) gave the aldehyde (−)-14. Horner–Emmons olefination of (−)-14 with triethyl 
phosphonoacetate gave the unsaturated ester 15(88%) which contains all of the carbons of the C3–C9 segment 
of 1. Brief (1 h) catalytic hydrogenation of 15 resulted in saturation of the C6–C7 olefin without removal of the 
BOM protecting group (79%). Hydrolysis of (−)-16 gave the carboxylic acid 17 (51%). The use of this segment in 
the synthesis of 1 will be reported in due course. 
 
Scheme. 3. Reagents: (a) MOMCl/iPr2NEt (95%); (b) DIBAL (92%); (c) BOMCl/iPr2NH (69%); (d) TBAF/THF (83%); 
(e) DMSO/(COCl)2/NEt3 (84%); (f) (EtO)2P(O)CH2CO2Et/NaH (88%); (g) H2/10% Pd–C (79%); (h) KOH/H2O/EtOH 
(51%) 
2. Experimental section 
2.1. General data 
Spectrograde solvents were used without purification with the exception of tetrahydrofuran which was distilled 
from the sodium benzophenone ketyl. Aldrich sure-seal dichloromethane and DMSO were used without further 
purification. Methyl (S)-3-hydroxy-2-methylpropionate and 4(R)-methyl-5(S)-phenyloxazolidin-2-one were 
purchased from the Aldrich Chemical Company, Inc. Column chromatography was performed on silica gel 60 
(0.04–0.063 mm, E. Merck or 60–200 mesh, Aldrich) and `flash' chromatography was performed on silica gel 60 
(230–400 mesh). Thin layer chromatography was performed on Merck (Kieselgel 60 F254) or Kodak Chromagram 
(silica gel without fluorescent indicator). 
All 1H NMR and 13C NMR spectra were recorded at 300 and 75 MHz respectively. Melting points were obtained 
on a Mel-Temp melting point apparatus and are uncorrected. Elemental analyses were obtained from Robertson 
Microlit Laboratories, Inc., Madison, NJ and high resolution mass spectra (EI) were obtained from the 
Washington University Resource for Mass Spectrometry. 
2.2. Methyl (S)-3-(tert-butyldiphenylsilyloxy)-2-methylpropionate ((+)-5) 
This was prepared from (S)-3-hydroxy-2-methylpropionate in a fashion similar to the procedure of Ley et 
al.[7] (93%) and was identified by comparison to the literature 1H NMR spectral data: [α]D +17 (c 2.5, CHCl3), 
(lit.[7] [α]D +23 (c 7.8, CH3OH)); Rf 0.38 (hexane:ethyl acetate=15:1). 
2.3. (R)-3-(tert-Butyldiphenylsilyloxy)-2-methyl-1-propanol ((+)-6) 
This was prepared by the reduction of (+)-5 with DIBAL in a fashion similar to the procedure of Ley et al.[7] (83%) 
and was identified by comparison to the literature 1H NMR spectral data: [α]D +6.1 (c 2.5, CHCl3), (lit.[7] [α]D +6.3 
(c 1.0, CHCl3)); Rf 0.27 (CH2Cl2). 
2.4. (S)-3-(tert-Butyldiphenylsilyloxy)-2-methylpropanal ((+)-7) 
This was prepared by oxidation of (+)-6 with DMSO/(COCl)2 in a fashion similar to the procedure of Roush et 
al.[7] The crude product was passed through a 3.5 inch bed of SiO2 (CH2Cl2) to give (+)-7 as a waxy solid (88%) 
which was identified by comparison to the literature 1H NMR spectral data: mp 61–63°C (lit.[7]a mp 51–61°C); 
[α]D +22 (c 1.0, CHCl3); Rf 0.20 (hexanes:CH2Cl2=2:1). 
2.5. Chiral aldol product ((+)-8) 
To a solution of N-propionyl-4(R)-methyl-5(S)-phenyloxazolidin-2-one (36.6 g, 157 mmol) in CH2Cl2(315 mL) 
cooled to 0°C was added dropwise freshly distilled dibutylboron triflate (47.3 g, 173 mmol) followed 
immediately by diisopropylethylamine (32.8 mL, 188 mmol). The mixture was stirred for 30 min, then cooled to 
−78°C whereupon a solution of (+)-7 in CH2Cl2 (157 mL) was added to the reaction mixture via a cannula transfer. 
The mixture was stirred for 30 min, warmed to rt, and stirred for an additional 90 min. The mixture was cooled 
to 0°C and pH 7 buffer (225 mL), methanol (600 mL) and 30% H2O2:methanol (1:1, 225 mL) were added in 
succession. The mixture was warmed to rt and stirred for 30 min, after which the phases separated. The 
aqueous layer was extracted twice with CH2Cl2, and the combined organic phases were dried (MgSO4) and 
concentrated. The residue was purified by flash chromatography (hexanes:ethyl acetate=12:1 to 8:1 gradient) to 
give (+)-8 as a colorless solid (78.4 g, 89%): mp 102–103°C; [α]D +22 (c 1.2, CHCl3); Rf 0.18 (hexanes:ethyl 
acetate=6:1); 1H NMR (CDCl3/D2O) δ 7.70–7.66 (m, 4H), 7.44–7.37 (m, 9H), 7.33–7.30 (m, 2H), 5.68 (d, J=7.0 Hz, 
1H), 4.78 (dq, 7.0, 6.6 Hz, 1H), 4.00–3.93 (m, 2H), 3.82 (dd, J=4.4, 9.9 Hz, 1H), 3.73 (d, J=6.6, 9.9 Hz, 1H), 1.90–
1.80 (m, 1H), 1.25 (d, J=6.6 Hz, 3H), 1.06 (s, 9H), 0.93 (d, J=7.0 Hz, 3H), 0.91 (d, J=6.2 Hz, 3H); 13C NMR (CDCl3) δ 
176.1, 152.6, 135.5, 133.2, 132.9, 132.8, 129.7, 128.6, 127.7, 125.5, 78.8, 75.1, 68.4, 55.0, 40.7, 37.5, 26.7, 19.1, 
14.2, 13.2, 9.1; EI-HRMS m/z 560.2828 (calcd for C33H42NO5Si (M+H)+ 560.2832); Anal. Calcd for C33H41NO5Si: C, 
70.81; H, 7.38; N, 2.50. Found: C, 70.54; H, 7.35; N, 2.45. A sample suitable for X-ray diffraction analysis[10]was 
obtained by recrystallization from hot methanol. 
2.6. Methyl (2R,3S,4S)-5-t-butyldiphenylsilyloxy-3-hydroxy-2,4-dimethylpentanoate ((+)-
9) 
To a freshly prepared solution of methanolic sodium methoxide (1.9 g Na/350 mL MeOH) at 0°C was slowly 
added a solution of (+)-8 (45.8 g, 81.8 mmol) in THF (250 mL). When 8 was no longer observed by TLC 
monitoring (ca. 15 min), saturated aqueous NH4Cl was added and the heterogenous mixture was partitioned 
between CH2Cl2/H2O. The layers were separated and the aqueous layer was extracted with CH2Cl2. All of the 
CH2Cl2 phases were combined, dried (MgSO4) and concentrated. The residue was purified by flash 
chromatography (hexanes:ethyl acetate=10:1) to give (+)-9 as a viscous oil (26.4 g, 78%): [α]D +6.8 (c 1.0, CHCl3); 
Rf 0.5 (hexanes:ethyl acetate=4:1); 1H NMR (CDCl3/D2O) δ 7.69–7.65 (m, 4H), 7.44–7.36 (m, 6H), 3.96 (dd, J=3.7, 
8.4 Hz, 1H), 3.83 (d, J=4.2, 10.3 Hz, 1H), 3.70 (d, J=6.3, 10.3 Hz, 1H), 3.70 (s, 3H), 2.63 (dq, J=7.0, 3.7 Hz, 1H), 
1.83–1.73 (m, 1H), 1.21 (d, J=7.0 Hz, 3H), 1.05 (s, 9H), 0.86 (d, J=7.0 Hz, 3H); MS (CI/NH3) m/z 415 (M+H)+, 432 
(M+NH4)+. 
2.7. Methyl (2R,3S,4S)-5-t-butyldiphenylsilyloxy-3-[methoxy(methoxy)]-2,4-
dimethylpentanoate ((+)-10) 
To a solution of (+)-9 (26.1 g, 62.9 mmol) in freshly distilled diisopropylethylamine (125 mL) at 0°C was slowly 
added, via a syringe, chloromethyl methyl ether (24.0 mL, 315 mmol). The reaction mixture was warmed to rt, 
and then heated at 38°C for 18 h. After cooling to rt, the reaction mixture was diluted with CH2Cl2 and washed 
with 0.25 N HCl (2×160 mL), followed by saturated aqueous NaHCO3, and brine:H2O (1:1), dried (MgSO4) and 
concentrated. The residue was purified by flash chromatography (hexanes:ethyl acetate=10:1) to give (+)-10 as a 
colorless oil which solidified upon storing in the freezer (27.5 g, 95%): mp 54.5–55.5°C; [α]D +4 (c 0.9, CHCl3); 
Rf 0.60 (hexanes:ethyl acetate=4:1); 1H NMR (CDCl3) δ 7.67–7.64 (m, 4H), 7.44–7.34 (m, 6H), 4.53 (d, J=6.6 Hz, 
1H), 4.45 (d, J=6.6 Hz, 1H), 3.93 (dd, J=3.7, 7.8 Hz, 1H), 3.73 (d, J=4.2, 10.3 Hz, 1H), 3.66 (s, 3H), 3.61 (dd, J=6.0, 
10.0 Hz, 1H), 3.19 (s, 3H), 2.70 (dq, J=7.0, 3.7 Hz, 1H), 1.90–1.80 (m, 1H), 1.14 (d, J=7.0 Hz, 3H), 1.07 (s, 9H), 0.99 
(d, J=7.0 Hz, 3H); MS (FAB) m/z 497 (M+K)+; Anal. Calcd for C26H38O5Si: C, 68.08; H, 8.35. Found: C, 67.93; H, 8.24. 
2.8. (2S,3R,4S)-5-t-Butyldiphenylsilyloxy-3[(methoxy)methoxy]-2,4-dimethyl-1-pentanol 
((+)-11) 
To a solution of (+)-10 (26.7 g, 58.3 mmol) in THF (120 mL) at −78°C was added dropwise a solution of DIBAL 
(128 mL, 1.0 M in toluene, 128 mmol). The mixture was stirred for 15 min, and then methanol was cautiously 
added until gas evolution ceased. The mixture was warmed to rt and partitioned between ethyl acetate and 1 M 
potassium sodium tartrate. The separated organic layer was washed with fresh 1 M potassium sodium tartrate, 
and the combined aqueous phases were extracted with CH2Cl2. All of the organic phases were combined, dried 
(MgSO4), and concentrated. The residue was purified by flash chromatography (hexanes:ethyl acetate=8:1 to 4:1 
gradient) to give (+)-11 as a viscous oil (23.0 g, 92%): [α]D +54 (c 1.0, CHCl3); Rf 0.25 (hexanes:ethyl 
acetate=4:1); 1H NMR (CDCl3/D2O) δ 7.66–7.62 (m, 4H), 7.45–7.34 (m, 6H), 4.68 (d, J=6.6 Hz, 1H), 4.43 (d, J=6.6 
Hz, 1H), 3.75–3.67 (m, 3H), 3.61 (d, J=7.7 Hz, 1H), 3.34 (s, 3H), 1.96–1.87 (m, 1H), 1.87–1.77 (m, 1H), 1.08 (s, 9H), 
0.94 (d, J=7.0 Hz, 3H), 0.76 (d, J=7.0 Hz, 3H); HRMS (CI) m/z 431.2603 (calcd for C25H39O4Si (M+H)+ 431.2618; 
Anal. Calcd for C25H38O4Si: C, 69.26; H, 8.90. Found: C, 69.72; H, 8.89. 
2.9. (2S,3R,4S)-1-[(Benzyloxy)methoxy]-5-t-butyldiphenylsilyloxy-3[(methoxy)methoxy]-
2,4-dimethyl-1-pentane ((+)-12) 
To a solution of (+)-11 (3.34 g, 7.76 mmol) in diisopropylamine (31 mL) at 0°C was added dropwise 
benzyloxymethyl chloride (8.0 mL, 46.6 mmol). The reaction mixture was gradually warmed to rt and stirred for 
18 h. The mixture was then heated at a gentle reflux for 24 h. The mixture was cooled and 2 N aqueous HCl was 
carefully added. The mixture was extracted with ethyl acetate and the combined extracts washed with 2 N 
aqueous HCl, brine, dried (MgSO4), and concentrated. The residue was purified by flash chromatography 
(hexanes:ethyl acetate=20:1) to give (+)-12 as an oil (2.95 g, 69%): [α]D+3.5 (c 1.4, CHCl3); Rf 0.17 (hexanes:ethyl 
acetate=15:1); 1H NMR (CDCl3) δ 7.67–7.63 (m, 4H), 7.43–7.27 (m, 11H), 4.97–4.49 (m, 6H), 3.74 (dd, J=3.9, 9.7 
Hz, 1H), 3.64–3.44 (m, 4H), 3.20 (s, 3H), 2.30–1.84 (m, 2H), 1.07 (s, 9H), 0.98 (d, J=7.0 Hz, 3H), 0.88 (d, J=7.0 Hz, 
3H); MS (CI/NH3) m/z 568 (M+NH4)+; Anal. Calcd for C33H46O5Si: C, 71.96; H, 8.42. Found: C, 71.83; H, 8.26. 
2.10. (2S,3S,4S)-5-[(Benzyloxy)methoxy]-3-[(methoxy)methoxy]-2,4-dimethyl-1-pentanol 
((−)-13) 
To a solution of (+)-12 (2.50 g, 4.65 mmol) in THF (18.5 mL) at 0°C was added a solution of tetrabutylammonium 
fluoride in THF (1.0 M, 4.9 mL, 4.9 mmol). Thr reaction mixture was warmed to rt and stirred for 3 h. The 
reaction mixture was poured into water and extracted with ether, the combined extracts dried (MgSO4), and 
concentrated. The residue was purified by flash chromatography (hexanes:ethyl acetate=4:1) to give (−)-13 as an 
oil (1.21 g, 83%): [α]D −42 (c 1.2, CHCl3); Rf 0.33 (hexanes:ethyl acetate=2:1); 1H NMR (CDCl3) δ 7.36–7.27 (m, 5H), 
4.79–4.61 (m, 6H), 3.88–3.81 (m, 1H), 3.65 (dd, J=2.2, 9.2 Hz, 1H), 3.56–3.47 (m, 3H), 3.43 (s, 3H), 2.93 (t, J=6.8 
Hz, OH), 2.07–1.97 (m, 1H), 1.88–1.79 (m, 1H), 0.96 (d, J=7.0 Hz, 3H), 0.88 (d, J=7.0 Hz, 3H); MS (CI/NH3) m/z 330 
(M+NH4)+; Anal. Calcd for C17H28O5: C, 65.36; H, 9.03. Found: C, 65.17; H, 9.08. 
2.11. (2R,3R,4S)-5-[(Benzyloxy)methoxy]-3-[(methoxy)methoxy]-2,4-dimethylpentanal 
((−)-14) 
To a solution of oxalyl chloride (1.4 mL, 16.5 mmol) in CH2Cl2 (25 mL) cooled to −78°C was added DMSO (2.1 mL, 
30 mmol), followed by dropwise addition of a solution of (−)-13 (4.7 g, 15 mmol) in CH2Cl2 (30 mL). The reaction 
mixture was stirred for 15 min and then triethylamine (6.3 mL, 45 mmol) was added. The reaction mixture was 
stirred at −78°C for 15 min, warmed to rt, and a solution of 1 N HCl was added. The phases were separated, and 
the organic phase washed with saturated aqueous NaHCO3, brine, dried (MgSO4), and concentrated. The residue 
was purified by flash chromatography (hexanes:ethyl acetate=8:1) to give (−)-14 as an oil (3.93 g, 84%): [α]D −27 
(c 0.9, CHCl3); Rf 0.17 (hexanes:ethyl acetate=8:1); 1H NMR (CDCl3) δ 9.72 (d, J=2.9 Hz, 1H), 7.42–7.26 (m, 5H), 
4.75 (s, 2H), 4.69 (d, J=6.8 Hz, 1H), 4.60 (d, J=6.8 Hz, 1H), 4.60 (m, 2H), 3.94 (dd, J=3.3, 7.4 Hz, 1H), 3.50 (d, J=7.0 
Hz, 2H), 3.33 (s, 3H), 2.70–2.60 (m, 1H), 2.04–1.97 (m, 1H), 1.07 (d, J=7.0 Hz, 3H), 0.94 (d, J=7.0 Hz, 3H); MS 
(CI/NH3) m/z 328 (M+NH4)+. 
2.12. Ethyl (2E,4S,5S,6S)-7-[(benzyloxy)methoxy]-5-[(methoxy)methoxy]-4,6-dimethyl-2-
heptenoate (15) 
To a slurry of NaH (415 mg, 13.8 mmol, 80% dispersion in mineral oil) in THF (25 mL) was added dropwise 
triethyl phosphonoacetate (2.7 mL, 13.8 mmol). After 15 min, a solution of (−)-14 (3.9 g, 12.6 mmol) in THF (25 
mL) was added. The reaction mixture was stirred for 18 h and then carefully quenched with 1 N aqueous HCl 
(140 mL). The phases were separated, and the aqueous phase extracted with ether. The combined organic 
phases were dried (MgSO4) and concentrated. The residue was purified by flash chromatography (hexanes:ethyl 
acetate=12:1) to give 15 as an oil (4.2 g, 88%): Rf 0.42 (hexanes:ethyl acetate=4:1); 1H NMR (CDCl3) δ 7.40–7.26 
(m, 5H), 7.03 (dd, J=8.5, 15.5 Hz, 1H), 5.85 (d, J=15.5 Hz, 1H), 4.75 (s, 2H), 4.64 (d, J=6.7 Hz, 1H), 4.60 (s, 2H), 4.58 
(d, J=6.7 Hz, 1H), 4.18 (q, J=7.0 Hz, 2H), 3.60–3.46 (m, 3H), 3.36 (s, 3H), 2.66–2.53 (m, 1H), 2.20–1.92 (m, 1H), 
1.28 (t, J=7.0 Hz, 3H), 1.07 (s, 3H), 0.94 (d, J=7.0 Hz, 3H); MS (CI/NH3) m/z 398 (M+NH4)+. 
2.13. Ethyl (4S,5S,6S)-7-[(benzyloxy)methoxy]-5-[(methoxy)methoxy]-4,6-
dimethylheptanoate ((−)-16) 
A solution of 15 (4.2 g, 11 mmol) and 10% Pd/C (360 mg) in ethyl acetate (22 mL) was stirred under an 
atmosphere of H2 (1 atm) for 14 h. The reaction mixture was filtered and concentrated. The residue was purified 
by flash chromatography (hexanes:ethyl acetate=15:1) to give 16 as an oil (3.3 g, 79%): [α]D−9.2 (c 1.0, CHCl3); 
Rf 0.42 (hexanes:ethyl acetate=4:1); 1H NMR (CDCl3) δ 7.38–7.26 (m, 5H), 4.76 (s, 2H), 4.68 (d, J=6.6 Hz, 1H), 4.63 
(d, J=6.6 Hz, 1H), 4.60 (s, 2H), 4.12 (q, J=7.0 Hz, 2H), 3.51–3.38 (m, 3H), 3.39 (s, 3H), 2.41 (ddd, J=5.5, 10.3, 15.6 
Hz, 1H), 2.26 (ddd, J=6.4, 9.7, 15.6 Hz, 1H), 2.04–1.89 (m, 2H), 1.76–1.64 (m, 1H), 1.51–1.39 (m, H), 1.25 (t, J=7.0 
Hz, 3H), 0.92 (d, J=7.0 Hz, 3H), 0.90 (d, J=7.0 Hz, 3H); 13C NMR (CDCl3) δ 173.9, 137.9, 128.4, 127.8, 127.6, 98.4, 
94.8, 83.4, 71.1, 69.4, 60.2, 56.0, 35.4, 35.2, 32.2, 27.8, 16.0, 14.2, 11.3; MS (CI/NH3) m/z 400 (M+NH4)+; EI-
HRMS m/z 321.2057 (calcd for C19H29O4 (M–OCH2OCH3)+ 321.2066). 
2.14. (4S,5S,6S)-7-[(Benzyloxy)methoxy]-5-[(methoxy)methoxy]-4,6-dimethylheptanoic 
acid (17) 
A solution of KOH (245 mg, 4.3 mmol) in water (3 mL) and ethanol (9 mL) was added to 16 (1.38 g, 3.6 mmol). 
The reaction mixture was stirred for 5 h. The mixture was acidified with excess 2 N HCl and extracted with 
CH2Cl2. All of the organic phases were combined, dried (MgSO4), and concentrated. The residue was purified by 
flash chromatography (CHCl3:MeOH=98:2) to give 17 as an oil (650 mg, 51%): 1H NMR (CDCl3) δ 7.36–7.26 (m, 
5H), 4.76 (s, 2H), 4.68 (d, J=6.6 Hz, 1H), 4.63 (d, J=6.6 Hz, 1H), 4.61 (s, 2H), 3.52–3.38 (m, 3H), 3.39 (s, 3H), 2.45 
(ddd, J=5.5, 10.3, 16.0 Hz, 1H), 2.36 (ddd, J=6.9, 9.9, 16.0 Hz, 1H), 2.05–1.91 (m, 2H), 1.78–1.68 (m, 1H), 1.52–
1.41 (m, H), 0.92 (d, J=6.7 Hz, 3H), 0.91 (d, J=6.6 Hz, 3H); 13C NMR (CDCl3) δ 179.7, 137.8, 128.4, 127.8, 127.6, 
98.3, 94.8, 83.4, 71.0, 69.4, 65.8, 56.0, 35.2, 31.8, 27.5, 15.9, 15.2; MS (CI/NH3) m/z 372 (M+NH4)+; Anal. Calcd 
for C19H30O6: C, 64.38; H, 8.53. Found: C, 63.90; H, 8.49. 
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